← Back to guidelines
Dermatology555 papers·2 edits

Impetiginized atopic dermatitis

Last edited: 4/15/2026

개요

아토피 피부염(AD)은 가려움을 동반한 병변과 피부 장벽 기능 저하를 특징으로 하는 만성 염증성 피부 질환이다. 감염된 AD는 주로 Staphylococcus aureus에 의한 이차적 세균 감염을 포함하며, 임상적 표현과 관리를 복잡하게 만든다 838.d

진단

  • 임상적 특징:
  • - 홍반과 가려움을 동반한 피부 병변의 전형적인 분포 패턴.
  • 이차 감염의 징후:
  • - 딱지, 농포, 또는 삼출물의 존재.
  • 감염 확인:
  • - S. aureus 및 기타 병원체에 대한 피부 긁힘 검사.
  • 심각도 평가:
  • - EASI, SCORAD, IGA, TIS Score 등의 점수 체계 사용 5.

    관리

  • 일차 치료:
  • - 염증과 가려움 완화를 위한 국소 스테로이드와 칼시뉴린 억제제. - 감염된 병변에 대한 항균 요법 (예: 국소 뮤피로신) 30.
  • 보조 치료:
  • - 중등도에서 중증의 경우 Janus 키나제 억제제 (예: 업다카티닙, 아보카티닙, 트라로키누맙) 410152229. - 치료에 반응하지 않는 경우 생물학적 제제 (예: 두필루맙) 91844.
  • 피부 장벽 지원:
  • - 세라마이드, 리놀레산, 덱스판테놀을 포함한 보습제와 보습제 사용 65.

    특수 인구 집단

  • 임신: 데이터가 제한적; 전신 약물 사용에 주의; 국소 치료에 초점 13.
  • 소아: 연령에 맞는 제형 고려 및 성장 및 발달 모니터링; dupilumab과 abrocitinib과 같은 전신 치료는 소아 임상 시험에서 효과와 안전성이 입증됨 1867.
  • 노인: 유사한 관리 원칙 적용; 동반 질환과 다약물 사용의 영향 고려 2.
  • 동반 질환: 천식 및 알레르기 비염과 같은 관련 질환 동시 관리; 치료의 전신 효과 모니터링 47.
  • 주요 권장 사항

  • 경미한 중등도 AD의 경우 국소 스테로이드와 칼시뉴린 억제제로 치료를 시작하고, 심각도와 반응에 따라 조정 5.
  • 이차 감염이 있는 병변에 국소 또는 전신 항균제 사용 30.
  • 치료에 반응하지 않는 경우 JAK 억제제 또는 생물학적 제제를 고려, 환자의 반응과 안전성 프로파일에 따라 4910152229.
  • 정기적으로 피부 장벽 기능을 평가하고 지원, 보습제와 보습제 사용 65.
  • 다중 건강 문제를 가진 환자의 포괄적인 관리를 위해 동반 질환 모니터링 및 관리 47.
  • (근거: 중등도)
  • 임산부에서는 전신 치료에 주의, 안전한 국소 치료 옵션을 우선 13.
  • (근거: 약함)

    References

    Showing 100 most recent of 524 indexed papers.

    1 Mandecka A, Perlak K, Bajek W, Kruczek W, Frątczak A, Polak K et al.. Review of Herpes Zoster Occurrence in Patients With Atopic Dermatitis Treated With JAK Inhibitors. Clinical and translational science 2026. link 2 Gaudenzio N, Basso L. A neuroimmune circuit links stress to skin inflammation. Science (New York, N.Y.) 2026. link 3 Bui JK, Stein AB, Maguiness S, Siegel DH. Scrolling for Solutions: Social Media Use Among Caregivers in Pediatric Dermatology. Pediatric dermatology 2026. link 4 Dogra S, Prarthana T, Sudharani G, Chhabra S. Upadacitinib in dermatology: A systematic review of mechanism, current applications, efficacy, safety, and emerging evidence. Indian journal of dermatology, venereology and leprology 2026. link 5 Waligóra-Dziwak K, Kubiak KB, Dańczak-Pazdrowska A, Jenerowicz D. How Adequately is the Severity of Atopic Dermatitis Assessed by Resident Physicians Training in Dermatology? Evaluation of the Intrarater and Interrater Reliability of Clinical Scoring Systems (EASI, oSCORAD, IGA, TIS Score, SASSAD). Acta dermato-venereologica 2026. link 6 Chang J, Perz A, Goldstein LJ, Shen LY, Lee MS. The Coping Clinic: An Interdisciplinary Pediatric Psychodermatology Clinic. Pediatric dermatology 2026. link 7 Nazeha N, Senanayake S, Cai Y, Koh MJA, Bing S, Hong W et al.. Mapping the Children's Dermatology Life Quality Index Questionnaire to EQ-5D-Y-3L in Pediatric Patients With Atopic Dermatitis. Value in health regional issues 2026. link 8 Krogh NS, Prieto-Merino D, Coker B, Birkner T, Akkoc A, Gribaleva E et al.. Implementing Federated Analysis Using DataSHIELD in the DREAM TO TREAT Atopic Dermatitis Registries Collaboration. The Journal of investigative dermatology 2026. link 9 Jiang Y, Sun X, Li Y. Investigating tralokinumab-related adverse events in treating atopic dermatitis: insights from the FAERS database. Frontiers in immunology 2026. link 10 Huang Y, Zhou Q, Ke C, Chen M. Postmarketing adverse events of biologics and Janus kinase inhibitors in patients with atopic dermatitis. Inflammopharmacology 2026. link 11 Saeki H, Ohya Y, Arakawa H, Ichiyama S, Katsunuma T, Katoh N et al.. English version of clinical practice guidelines for the management of atopic dermatitis 2024. The Journal of dermatology 2025. link 12 Davis DMR, Frazer-Green L, Alikhan A, Bercovitch L, Cohen DE, Darr JM et al.. Focused update: Guidelines of care for the management of atopic dermatitis in adults. Journal of the American Academy of Dermatology 2025. link 13 Sánchez-García V, De-Miguel-Balsa E, Ramos-Rincón JM, Belinchón-Romero I. Safety of Dupilumab Therapy for Atopic Dermatitis during Pregnancy: A Systematic Review and Meta-analysis. Acta dermato-venereologica 2025. link 14 Park M, Mohsen ST, Katz T, Sood S, Sy SMT, Rochwerg B et al.. Climate Conditions, Weather Changes, and Air Pollutants and Atopic Dermatitis: A Meta-Analysis. JAMA dermatology 2025. link 15 Rønnstad ATM, Bunick CG, Chovatiya R, Kamata M, Nielsen ML, Isufi D et al.. Real-World Evidence of Tralokinumab Effectiveness and Safety: A Systematic Review and Meta-analysis. American journal of clinical dermatology 2025. link 16 Chang JW, Huang X, Jiang W, Lun L, Liu W, Xu R et al.. Abrocitinib versus dupilumab: Impact on skin barrier function and proteomics in atopic dermatitis. Journal of the American Academy of Dermatology 2025. link 17 Saeki H, Ohya Y, Arakawa H, Ichiyama S, Katsunuma T, Katoh N et al.. Executive summary: Japanese guidelines for atopic dermatitis (ADGL) 2024. Allergology international : official journal of the Japanese Society of Allergology 2025. link 18 Rossi AB, Mello AM, Zahn J. Dupilumab Efficacy in Children with Atopic Dermatitis with Different Phenotypes and Endotypes: A Case Series. Advances in therapy 2025. link 19 Pinborg EH, Laursen SB, Thein D, Vittrup I, Schlapbach C, Maul JT et al.. Preferences in atopic dermatitis: A systematic review. Journal of the European Academy of Dermatology and Venereology : JEADV 2025. link 20 Liao Q, Pan H, Guo Y, Lan Y, Huang Z, Wu P. Comparative efficacy and safety of dupilumab versus newly approved biologics and JAKi in pediatric atopic dermatitis: A systematic review and network meta-analysis. PloS one 2025. link 21 Oliva M, Sarkar MK, March ME, Saeidian AH, Mentch FD, Hsieh CL et al.. Integration of GWAS, QTLs and keratinocyte functional assays reveals molecular mechanisms of atopic dermatitis. Nature communications 2025. link 22 Kim Y, Seo G, Koopman JJE, Yee J. Real-World Effectiveness and Safety of JAK Inhibitors in Atopic Dermatitis: A Systematic Review and Meta-Analysis. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 2025. link 23 Kawamoto N, Murai H, Nogami K, Yamamoto T, Kikkawa T, Yasutomi-Sakai M et al.. Efficacy and safety of systemic targeted therapies for atopic dermatitis in children: A systematic review and meta-analysis. Allergology international : official journal of the Japanese Society of Allergology 2025. link 24 Liu X, Luo Y, Chen X, Wu M, Xu X, Tian J et al.. Fecal microbiota transplantation against moderate-to-severe atopic dermatitis: A randomized, double-blind controlled explorer trial. Allergy 2025. link 25 Li W, Pi Y, Xu J. Association between atopic dermatitis and prurigo nodularis: a systematic review and meta-analysis. International journal of dermatology 2025. link 26 Mahajan R, Sarkar R, Panda M, Katakam BK, Padhiyar J, Haritha T et al.. Evidence-Based Recommendations for Managing Atopic Dermatitis in Pediatric Patients: A Systematic Review and Meta-Analysis From the Pediatric Dermatology Special Interest Group of IADVL. International journal of dermatology 2025. link 27 Guo J, Bai R, Luo R, Lin L, Zheng Y. Angiostatin: a promising therapeutic target for atopic dermatitis. Archives of dermatological research 2025. link 28 Guttman-Yassky E, Katoh N, J Cork M, Jagdeo J, F Alexis A, Chen Z et al.. Dupilumab Treatment Improves Lichenification in Atopic Dermatitis in Different Age and Racial Groups. Journal of drugs in dermatology : JDD 2025. link 29 Cork MJ, Deleuran M, Geng B, Silverberg JI, Simpson EL, Stein Gold LF et al.. Long-Term Safety of Abrocitinib in Moderate-to-Severe Atopic Dermatitis: Integrated Analysis by Age. The journal of allergy and clinical immunology. In practice 2025. link 30 Tingting L, Zhang P, Yang L, Li R, Wang R. The effects of topical antimicrobial-corticosteroid combination therapy in comparison to topical steroids alone on the skin microbiome of patients with atopic dermatitis. The Journal of dermatological treatment 2025. link 31 Wang Y, Chen Z, He T, Huang C, Shen C. Risk of incident venous thromboembolism in patients with atopic dermatitis: systematic analysis of the literature and meta-analysis. Journal of thrombosis and thrombolysis 2025. link 32 Matwiejuk M, Myśliwiec H, Mikłosz A, Chabowski A, Flisiak I. Is Atopic Dermatitis Associated with Systemic Metabolic Disturbances? A Systematic Review. International journal of molecular sciences 2025. link 33 . Abstracts from 15th Georg Rajka International Symposium on Atopic Dermatitis. Acta dermato-venereologica 2025. link 34 Truong K, Luu W, Fernandez-Penas P. Reliability of Clinical Scoring Tools in Teledermatology Compared to Face-To-Face Assessment: A Systematic Review and Meta-Analysis. The Australasian journal of dermatology 2025. link 35 Yu H, Zhu J, Ni X, Yu K, Mu Z. Off-label use of upadacitinib in dermatology: a review. The Journal of dermatological treatment 2025. link 36 Awad A, Bell F, Ross G. Topical Steroid Withdrawal: A Perspective of Australian Dermatologists. The Australasian journal of dermatology 2025. link 37 Park JJ, Richards D, Tseng PH, Ebata T, Ikoma A, Vakharia PP et al.. Methods to Validate Digital Health Technologies for Dermatology. The Journal of investigative dermatology 2025. link 38 Schachner LA, Andriessen A, Benjamin L, Gonzalez ME, Kwong P, Lio P et al.. SAIGE II: The Role of Staphylococcus aureus in Skin Barrier Dysfunction and the Development and Severity of Atopic Dermatitis in Young Children. Journal of drugs in dermatology : JDD 2025. link 39 Fritzsche MC, Hangel N, Buyx AM. Ethical challenges in biomarker research and precision medicine - a qualitative study in dermatology. BMC medical ethics 2025. link 40 Edmonds NL, Heron CE, Lawrence MG, Zlotoff B. Differences between allergy and dermatology in referral, evaluation, and management patterns for pediatric patients with atopic dermatitis. The Journal of dermatological treatment 2025. link 41 Orschanski D, Rubén Dandeu LN, Rivero MN, Labovsky V, Fernández EA. Dermatological implications of alignment-based de-hosting and bioinformatics pipelines on shotgun microbiome analysis. Journal of translational medicine 2025. link 42 Rademaker M, Foley P, Armour K, Baker C, Gebauer K, Gupta M et al.. Consensus on the Use of JAKinibs for Atopic Dermatitis in Australia and New Zealand. An eDelphi by the Australasian Medical Dermatology Group. The Australasian journal of dermatology 2025. link 43 Connell T, Seidler K, Neil J. Cathelicidin expression in the pathogenesis of atopic dermatitis and the therapeutic potential of vitamin D. Nutrition research (New York, N.Y.) 2025. link 44 Zhou J, Xie Y, Du P, Chen M, Liu X. Analysis of differences in dupilumab-associated adverse drug event signals between children and adults based on the FAERS database. European journal of pharmacology 2025. link 45 Gao H, Cao L, Liu C. Analysis and mining of Dupilumab adverse events based on FAERS database. Scientific reports 2025. link 46 Zhu Z, Liu M, Zhang H, Zheng H, Li J. Post-marketing safety concerns with abrocitinib: a real-world pharmacovigilance analysis of the FDA adverse event reporting system. Expert opinion on drug safety 2025. link 47 Chu DK, Schneider L, Asiniwasis RN, Boguniewicz M, De Benedetto A, Ellison K et al.. Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based recommendations. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 2024. link 48 Werfel T, Heratizadeh A, Aberer W, Augustin M, Biedermann T, Bauer A et al.. S3 guideline Atopic dermatitis: Part 2 - Systemic treatment. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2024. link 49 He Q, Xie X, Chen Q, Li W, Song Z, Wang X et al.. Janus kinase inhibitors in atopic dermatitis: an umbrella review of meta-analyses. Frontiers in immunology 2024. link 50 Werfel T, Heratizadeh A, Aberer W, Augustin M, Biedermann T, Bauer A et al.. S3 Guideline Atopic dermatitis: Part 1 - General aspects, topical and non-drug therapies, special patient groups. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2024. link 51 Elhage KG, Kranyak A, Jin JQ, Haran K, Spencer RK, Smith PL et al.. Mendelian Randomization Studies in Atopic Dermatitis: A Systematic Review. The Journal of investigative dermatology 2024. link 52 Verma L, Turk T, Dennett L, Dytoc M. Teledermatology in Atopic Dermatitis: A Systematic Review. Journal of cutaneous medicine and surgery 2024. link 53 Argenziano G, Cusano F, Corazza M, Amato S, Amerio P, Naldi L et al.. Italian S3-Guideline on the treatment of Atopic Eczema - Part 2: non-systemic treatments and treatment recommendations for special AE patient populations, adapted from EuroGuiDerm by the Italian Society of Dermatology and STD (SIDEMAST), the Italian Association of Hospital Dermatologists (ADOI) and the Italian Society of Allergological and Occupational Dermatology (SIDAPA). Italian journal of dermatology and venereology 2024. link 54 Argenziano G, Cusano F, Corazza M, Amato S, Amerio P, Naldi L et al.. Italian S3-Guideline on the treatment of Atopic Eczema - Part 1: Systemic therapy, adapted from EuroGuiDerm by the Italian Society of Dermatology and STD (SIDEMAST), the Italian Association of Hospital Dermatologists (ADOI) and the Italian Society of Allergological and Environmental Dermatology (SIDAPA). Italian journal of dermatology and venereology 2024. link 55 Davis DMR, Drucker AM, Alikhan A, Bercovitch L, Cohen DE, Darr JM et al.. Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. Journal of the American Academy of Dermatology 2024. link 56 Drucker AM, Lam M, Prieto-Merino D, Malek R, Ellis AG, Yiu ZZN et al.. Systemic Immunomodulatory Treatments for Atopic Dermatitis: Living Systematic Review and Network Meta-Analysis Update. JAMA dermatology 2024. link 57 Edwards SJ, Karner C, Jhita T, Barton S, Marceniuk G, Yiu ZZN et al.. Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis. Health technology assessment (Winchester, England) 2024. link 58 Lieberman JA, Chu DK, Ahmed T, Dribin TE, Abrams EM, Anagnostou A et al.. A systematic review and expert Delphi Consensus recommendation on the use of vaccines in patients receiving dupilumab: A position paper of the American College of Allergy, Asthma and Immunology. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 2024. link 59 Vassilopoulou E, Comotti A, Douladiris N, Konstantinou GΝ, Zuberbier T, Alberti I et al.. A systematic review and meta-analysis of nutritional and dietary interventions in randomized controlled trials for skin symptoms in children with atopic dermatitis and without food allergy: An EAACI task force report. Allergy 2024. link 60 Singleton H, Hodder A, Almilaji O, Ersser SJ, Heaslip V, O'Meara S et al.. Educational and psychological interventions for managing atopic dermatitis (eczema). The Cochrane database of systematic reviews 2024. link 61 Nielsen AY, Høj S, Thomsen SF, Meteran H. Vitamin D Supplementation for Treating Atopic Dermatitis in Children and Adults: A Systematic Review and Meta-Analysis. Nutrients 2024. link 62 Eichenfield LF, Boguniewicz M, Lauren CT, Leung DYM, Levy ML, Schneider LC et al.. Systemic Therapy for Atopic Dermatitis in Children and Adolescents: A US Expert Consensus. Dermatology (Basel, Switzerland) 2024. link 63 Liang S, Huang KY, Zhang L, Li M, Gu HH, Chen NG. Acupuncture for atopic dermatitis: a systematic review and meta-analysis. BMJ open 2024. link 64 Yoon S, Kim K, Shin K, Kim HS, Kim B, Kim MB et al.. The safety of systemic Janus kinase inhibitors in atopic dermatitis: A systematic review and meta-analysis of randomized controlled trials. Journal of the European Academy of Dermatology and Venereology : JEADV 2024. link 65 Somjorn P, Kamanamool N, Kanokrungsee S, Rojhirunsakool S, Udompataikul M. A cream containing linoleic acid, 5% dexpanthenol and ceramide in the treatment of atopic dermatitis. Asian Pacific journal of allergy and immunology 2024. link 66 Guttman-Yassky E, Facheris P, Gomez-Arias PJ, Del Duca E, Da Rosa JC, Weidinger S et al.. Effect of abrocitinib on skin biomarkers in patients with moderate-to-severe atopic dermatitis. Allergy 2024. link 67 Zheng Y, Ding RL, Bu J. Effectiveness and safety of systemic therapy for moderate-to-severe atopic dermatitis in children and adolescent patients: a systematic review. Frontiers in immunology 2024. link 68 Zhao SS, Yiu ZZN. Genetically proxied IL-6 receptor inhibition is associated with increased risk of atopic dermatitis. The Journal of allergy and clinical immunology 2024. link 69 Starrenburg ME, Bel Imam M, Lopez JF, Buergi L, Nguyen NT, Nouwen AEM et al.. Dupilumab treatment decreases MBC2s, correlating with reduced IgE levels in pediatric atopic dermatitis. The Journal of allergy and clinical immunology 2024. link 70 Wollenberg A, Ikeda M, Chu CY, Eichenfield LF, Seyger MMB, Prakash A et al.. Longer-term safety and efficacy of baricitinib for atopic dermatitis in pediatric patients 2 to <18 years old: a randomized clinical trial of extended treatment to 3.6 years. The Journal of dermatological treatment 2024. link 71 Sesi J, Feldman SR. Comparative efficacy of systemic treatments for atopic dermatitis in adults. Expert review of clinical immunology 2024. link 72 Davis DMR, Drucker AM, Alikhan A, Bercovitch L, Cohen DE, Darr JM et al.. Executive summary: Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. Journal of the American Academy of Dermatology 2024. link 73 Ahuja K, DeSena G, Lio P. Analysis of Reddit Reveals JAK Inhibitor Questions Among Atopic Dermatitis Patients. Journal of drugs in dermatology : JDD 2024. link 74 Zhu J. A pathway linking atopic dermatitis to skin microbes. Cell host & microbe 2024. link 75 Hoeger PH. Dupilumab: Two sides of a side-effect. Pediatric dermatology 2024. link 76 Greener M. Atopic dermatitis: new insights into a common condition. British journal of community nursing 2024. link 77 Robinson L, Strowd LC. American Academy of Dermatology Guidelines for Managing Atopic Dermatitis. Advances in experimental medicine and biology 2024. link 78 Wieser JK, Larson BI, Shah SD. From flare to care: Dermatologists' impact on pediatric atopic dermatitis hospital admissions. Pediatric dermatology 2024. link 79 Langenbruch A, Andrees V, Scherer M, Augustin M. Healthcare of patients with atopic dermatitis by general practitioners - a nationwide survey in Germany. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2024. link 80 Odeshi O, Turk T, Fiorillo L, Lowe S, Dytoc M. Teledermatology Versus In-Person Visits for the Follow-Up of Atopic Dermatitis Patients. Journal of cutaneous medicine and surgery 2024. link 81 Renert-Yuval Y, Del Duca E, Arents B, Bissonnette R, Drucker AM, Flohr C et al.. Treat-to-target in dermatology: A scoping review and International Eczema Council survey on the approach in atopic dermatitis. Journal of the European Academy of Dermatology and Venereology : JEADV 2024. link 82 Schlösser AR, Boeijink N, Olydam J, Nijsten TEC, Hijnen D. Upadacitinib treatment in a real-world difficult-to-treat atopic dermatitis patient cohort. Journal of the European Academy of Dermatology and Venereology : JEADV 2024. link 83 Yu T, Chen J, Wu S, Jiang M, Han L, Ma Y. Potential functionality of Cutibacterium acnes extracellular vesicles in atopic dermatitis and acne vulgaris: A comparative proteomic analysis. Proteomics. Clinical applications 2024. link 84 Conway AE, Kartha N, Maddukuri C, Shaker MS. Pearls for practice from the 2023 allergy immunology joint task force on practice parameters GRADE and institute of medicine based atopic dermatitis guidelines. Current opinion in pediatrics 2024. link 85 Borzutzky A, Iturriaga C, Pérez-Mateluna G, Cristi F, Cifuentes L, Silva-Valenzuela S et al.. Effect of weekly vitamin D supplementation on the severity of atopic dermatitis and type 2 immunity biomarkers in children: A randomized controlled trial. Journal of the European Academy of Dermatology and Venereology : JEADV 2024. link 86 Chen M, Ke C, Huang Y. Herpes virus reactivation induced by abrocitinib: A real-world pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database. Diagnostic microbiology and infectious disease 2024. link 87 Chu AWL, Wong MM, Rayner DG, Guyatt GH, Díaz Martinez JP, Ceccacci R et al.. Systemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials. The Journal of allergy and clinical immunology 2023. link 88 Chu DK, Chu AWL, Rayner DG, Guyatt GH, Yepes-Nuñez JJ, Gomez-Escobar L et al.. Topical treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials. The Journal of allergy and clinical immunology 2023. link 89 Yepes-Nuñez JJ, Guyatt GH, Gómez-Escobar LG, Pérez-Herrera LC, Chu AWL, Ceccaci R et al.. Allergen immunotherapy for atopic dermatitis: Systematic review and meta-analysis of benefits and harms. The Journal of allergy and clinical immunology 2023. link 90 Devasenapathy N, Chu A, Wong M, Srivastava A, Ceccacci R, Lin C et al.. Cancer risk with topical calcineurin inhibitors, pimecrolimus and tacrolimus, for atopic dermatitis: a systematic review and meta-analysis. The Lancet. Child & adolescent health 2023. link00283-8) 91 Sidbury R, Alikhan A, Bercovitch L, Cohen DE, Darr JM, Drucker AM et al.. Executive summary: American Academy of Dermatology guidelines of care for the management of atopic dermatitis in adults with topical therapies. Journal of the American Academy of Dermatology 2023. link 92 Husein-ElAhmed H, Steinhoff M. Meta-analysis on preventive and therapeutic effects of probiotic supplementation in infant atopic dermatitis. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2023. link 93 Tian J, Zhang D, Yang Y, Huang Y, Wang L, Yao X et al.. Global epidemiology of atopic dermatitis: a comprehensive systematic analysis and modelling study. The British journal of dermatology 2023. link 94 Sidbury R, Alikhan A, Bercovitch L, Cohen DE, Darr JM, Drucker AM et al.. Guidelines of care for the management of atopic dermatitis in adults with topical therapies. Journal of the American Academy of Dermatology 2023. link 95 Wang Q, Liu L, Gao S, Su S. Guidelines for the Management of Atopic Dermatitis in Children: A Systematic Review. International archives of allergy and immunology 2023. link 96 Budu-Aggrey A, Kilanowski A, Sobczyk MK, Shringarpure SS, Mitchell R, Reis K et al.. European and multi-ancestry genome-wide association meta-analysis of atopic dermatitis highlights importance of systemic immune regulation. Nature communications 2023. link 97 Geba GP, Li D, Xu M, Mohammadi K, Attre R, Ardeleanu M et al.. Attenuating the atopic march: Meta-analysis of the dupilumab atopic dermatitis database for incident allergic events. The Journal of allergy and clinical immunology 2023. link 98 Zhao S, Hwang A, Miller C, Lio P. Safety of topical medications in the management of paediatric atopic dermatitis: An updated systematic review. British journal of clinical pharmacology 2023. link 99 Freitas E, Torres T. New molecules for atopic dermatitis treatment beyond biological therapy. Current opinion in allergy and clinical immunology 2023. link 100 Saeki H, Akiyama M, Abe M, Igarashi A, Imafuku S, Ohya Y et al.. English version of Japanese guidance for biologics in treating atopic dermatitis. The Journal of dermatology 2023. link

    Original source

    1. [1]
      Review of Herpes Zoster Occurrence in Patients With Atopic Dermatitis Treated With JAK Inhibitors.Mandecka A, Perlak K, Bajek W, Kruczek W, Frątczak A, Polak K et al. Clinical and translational science (2026)
    2. [2]
      A neuroimmune circuit links stress to skin inflammation.Gaudenzio N, Basso L Science (New York, N.Y.) (2026)
    3. [3]
      Scrolling for Solutions: Social Media Use Among Caregivers in Pediatric Dermatology.Bui JK, Stein AB, Maguiness S, Siegel DH Pediatric dermatology (2026)
    4. [4]
      Upadacitinib in dermatology: A systematic review of mechanism, current applications, efficacy, safety, and emerging evidence.Dogra S, Prarthana T, Sudharani G, Chhabra S Indian journal of dermatology, venereology and leprology (2026)
    5. [5]
    6. [6]
      The Coping Clinic: An Interdisciplinary Pediatric Psychodermatology Clinic.Chang J, Perz A, Goldstein LJ, Shen LY, Lee MS Pediatric dermatology (2026)
    7. [7]
      Mapping the Children's Dermatology Life Quality Index Questionnaire to EQ-5D-Y-3L in Pediatric Patients With Atopic Dermatitis.Nazeha N, Senanayake S, Cai Y, Koh MJA, Bing S, Hong W et al. Value in health regional issues (2026)
    8. [8]
      Implementing Federated Analysis Using DataSHIELD in the DREAM TO TREAT Atopic Dermatitis Registries Collaboration.Krogh NS, Prieto-Merino D, Coker B, Birkner T, Akkoc A, Gribaleva E et al. The Journal of investigative dermatology (2026)
    9. [9]
    10. [10]
    11. [11]
      English version of clinical practice guidelines for the management of atopic dermatitis 2024.Saeki H, Ohya Y, Arakawa H, Ichiyama S, Katsunuma T, Katoh N et al. The Journal of dermatology (2025)
    12. [12]
      Focused update: Guidelines of care for the management of atopic dermatitis in adults.Davis DMR, Frazer-Green L, Alikhan A, Bercovitch L, Cohen DE, Darr JM et al. Journal of the American Academy of Dermatology (2025)
    13. [13]
      Safety of Dupilumab Therapy for Atopic Dermatitis during Pregnancy: A Systematic Review and Meta-analysis.Sánchez-García V, De-Miguel-Balsa E, Ramos-Rincón JM, Belinchón-Romero I Acta dermato-venereologica (2025)
    14. [14]
      Climate Conditions, Weather Changes, and Air Pollutants and Atopic Dermatitis: A Meta-Analysis.Park M, Mohsen ST, Katz T, Sood S, Sy SMT, Rochwerg B et al. JAMA dermatology (2025)
    15. [15]
      Real-World Evidence of Tralokinumab Effectiveness and Safety: A Systematic Review and Meta-analysis.Rønnstad ATM, Bunick CG, Chovatiya R, Kamata M, Nielsen ML, Isufi D et al. American journal of clinical dermatology (2025)
    16. [16]
      Abrocitinib versus dupilumab: Impact on skin barrier function and proteomics in atopic dermatitis.Chang JW, Huang X, Jiang W, Lun L, Liu W, Xu R et al. Journal of the American Academy of Dermatology (2025)
    17. [17]
      Executive summary: Japanese guidelines for atopic dermatitis (ADGL) 2024.Saeki H, Ohya Y, Arakawa H, Ichiyama S, Katsunuma T, Katoh N et al. Allergology international : official journal of the Japanese Society of Allergology (2025)
    18. [18]
    19. [19]
      Preferences in atopic dermatitis: A systematic review.Pinborg EH, Laursen SB, Thein D, Vittrup I, Schlapbach C, Maul JT et al. Journal of the European Academy of Dermatology and Venereology : JEADV (2025)
    20. [20]
    21. [21]
      Integration of GWAS, QTLs and keratinocyte functional assays reveals molecular mechanisms of atopic dermatitis.Oliva M, Sarkar MK, March ME, Saeidian AH, Mentch FD, Hsieh CL et al. Nature communications (2025)
    22. [22]
      Real-World Effectiveness and Safety of JAK Inhibitors in Atopic Dermatitis: A Systematic Review and Meta-Analysis.Kim Y, Seo G, Koopman JJE, Yee J Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2025)
    23. [23]
      Efficacy and safety of systemic targeted therapies for atopic dermatitis in children: A systematic review and meta-analysis.Kawamoto N, Murai H, Nogami K, Yamamoto T, Kikkawa T, Yasutomi-Sakai M et al. Allergology international : official journal of the Japanese Society of Allergology (2025)
    24. [24]
    25. [25]
    26. [26]
    27. [27]
      Angiostatin: a promising therapeutic target for atopic dermatitis.Guo J, Bai R, Luo R, Lin L, Zheng Y Archives of dermatological research (2025)
    28. [28]
      Dupilumab Treatment Improves Lichenification in Atopic Dermatitis in Different Age and Racial Groups.Guttman-Yassky E, Katoh N, J Cork M, Jagdeo J, F Alexis A, Chen Z et al. Journal of drugs in dermatology : JDD (2025)
    29. [29]
      Long-Term Safety of Abrocitinib in Moderate-to-Severe Atopic Dermatitis: Integrated Analysis by Age.Cork MJ, Deleuran M, Geng B, Silverberg JI, Simpson EL, Stein Gold LF et al. The journal of allergy and clinical immunology. In practice (2025)
    30. [30]
    31. [31]
      Risk of incident venous thromboembolism in patients with atopic dermatitis: systematic analysis of the literature and meta-analysis.Wang Y, Chen Z, He T, Huang C, Shen C Journal of thrombosis and thrombolysis (2025)
    32. [32]
      Is Atopic Dermatitis Associated with Systemic Metabolic Disturbances? A Systematic Review.Matwiejuk M, Myśliwiec H, Mikłosz A, Chabowski A, Flisiak I International journal of molecular sciences (2025)
    33. [33]
    34. [34]
    35. [35]
      Off-label use of upadacitinib in dermatology: a review.Yu H, Zhu J, Ni X, Yu K, Mu Z The Journal of dermatological treatment (2025)
    36. [36]
      Topical Steroid Withdrawal: A Perspective of Australian Dermatologists.Awad A, Bell F, Ross G The Australasian journal of dermatology (2025)
    37. [37]
      Methods to Validate Digital Health Technologies for Dermatology.Park JJ, Richards D, Tseng PH, Ebata T, Ikoma A, Vakharia PP et al. The Journal of investigative dermatology (2025)
    38. [38]
      SAIGE II: The Role of Staphylococcus aureus in Skin Barrier Dysfunction and the Development and Severity of Atopic Dermatitis in Young Children.Schachner LA, Andriessen A, Benjamin L, Gonzalez ME, Kwong P, Lio P et al. Journal of drugs in dermatology : JDD (2025)
    39. [39]
    40. [40]
      Differences between allergy and dermatology in referral, evaluation, and management patterns for pediatric patients with atopic dermatitis.Edmonds NL, Heron CE, Lawrence MG, Zlotoff B The Journal of dermatological treatment (2025)
    41. [41]
      Dermatological implications of alignment-based de-hosting and bioinformatics pipelines on shotgun microbiome analysis.Orschanski D, Rubén Dandeu LN, Rivero MN, Labovsky V, Fernández EA Journal of translational medicine (2025)
    42. [42]
      Consensus on the Use of JAKinibs for Atopic Dermatitis in Australia and New Zealand. An eDelphi by the Australasian Medical Dermatology Group.Rademaker M, Foley P, Armour K, Baker C, Gebauer K, Gupta M et al. The Australasian journal of dermatology (2025)
    43. [43]
      Cathelicidin expression in the pathogenesis of atopic dermatitis and the therapeutic potential of vitamin D.Connell T, Seidler K, Neil J Nutrition research (New York, N.Y.) (2025)
    44. [44]
    45. [45]
      Analysis and mining of Dupilumab adverse events based on FAERS database.Gao H, Cao L, Liu C Scientific reports (2025)
    46. [46]
    47. [47]
      Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based recommendations.Chu DK, Schneider L, Asiniwasis RN, Boguniewicz M, De Benedetto A, Ellison K et al. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2024)
    48. [48]
      S3 guideline Atopic dermatitis: Part 2 - Systemic treatment.Werfel T, Heratizadeh A, Aberer W, Augustin M, Biedermann T, Bauer A et al. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG (2024)
    49. [49]
      Janus kinase inhibitors in atopic dermatitis: an umbrella review of meta-analyses.He Q, Xie X, Chen Q, Li W, Song Z, Wang X et al. Frontiers in immunology (2024)
    50. [50]
      S3 Guideline Atopic dermatitis: Part 1 - General aspects, topical and non-drug therapies, special patient groups.Werfel T, Heratizadeh A, Aberer W, Augustin M, Biedermann T, Bauer A et al. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG (2024)
    51. [51]
      Mendelian Randomization Studies in Atopic Dermatitis: A Systematic Review.Elhage KG, Kranyak A, Jin JQ, Haran K, Spencer RK, Smith PL et al. The Journal of investigative dermatology (2024)
    52. [52]
      Teledermatology in Atopic Dermatitis: A Systematic Review.Verma L, Turk T, Dennett L, Dytoc M Journal of cutaneous medicine and surgery (2024)
    53. [53]
    54. [54]
    55. [55]
      Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies.Davis DMR, Drucker AM, Alikhan A, Bercovitch L, Cohen DE, Darr JM et al. Journal of the American Academy of Dermatology (2024)
    56. [56]
      Systemic Immunomodulatory Treatments for Atopic Dermatitis: Living Systematic Review and Network Meta-Analysis Update.Drucker AM, Lam M, Prieto-Merino D, Malek R, Ellis AG, Yiu ZZN et al. JAMA dermatology (2024)
    57. [57]
      Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis.Edwards SJ, Karner C, Jhita T, Barton S, Marceniuk G, Yiu ZZN et al. Health technology assessment (Winchester, England) (2024)
    58. [58]
      A systematic review and expert Delphi Consensus recommendation on the use of vaccines in patients receiving dupilumab: A position paper of the American College of Allergy, Asthma and Immunology.Lieberman JA, Chu DK, Ahmed T, Dribin TE, Abrams EM, Anagnostou A et al. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2024)
    59. [59]
    60. [60]
      Educational and psychological interventions for managing atopic dermatitis (eczema).Singleton H, Hodder A, Almilaji O, Ersser SJ, Heaslip V, O'Meara S et al. The Cochrane database of systematic reviews (2024)
    61. [61]
    62. [62]
      Systemic Therapy for Atopic Dermatitis in Children and Adolescents: A US Expert Consensus.Eichenfield LF, Boguniewicz M, Lauren CT, Leung DYM, Levy ML, Schneider LC et al. Dermatology (Basel, Switzerland) (2024)
    63. [63]
      Acupuncture for atopic dermatitis: a systematic review and meta-analysis.Liang S, Huang KY, Zhang L, Li M, Gu HH, Chen NG BMJ open (2024)
    64. [64]
      The safety of systemic Janus kinase inhibitors in atopic dermatitis: A systematic review and meta-analysis of randomized controlled trials.Yoon S, Kim K, Shin K, Kim HS, Kim B, Kim MB et al. Journal of the European Academy of Dermatology and Venereology : JEADV (2024)
    65. [65]
      A cream containing linoleic acid, 5% dexpanthenol and ceramide in the treatment of atopic dermatitis.Somjorn P, Kamanamool N, Kanokrungsee S, Rojhirunsakool S, Udompataikul M Asian Pacific journal of allergy and immunology (2024)
    66. [66]
      Effect of abrocitinib on skin biomarkers in patients with moderate-to-severe atopic dermatitis.Guttman-Yassky E, Facheris P, Gomez-Arias PJ, Del Duca E, Da Rosa JC, Weidinger S et al. Allergy (2024)
    67. [67]
    68. [68]
      Genetically proxied IL-6 receptor inhibition is associated with increased risk of atopic dermatitis.Zhao SS, Yiu ZZN The Journal of allergy and clinical immunology (2024)
    69. [69]
      Dupilumab treatment decreases MBC2s, correlating with reduced IgE levels in pediatric atopic dermatitis.Starrenburg ME, Bel Imam M, Lopez JF, Buergi L, Nguyen NT, Nouwen AEM et al. The Journal of allergy and clinical immunology (2024)
    70. [70]
      Longer-term safety and efficacy of baricitinib for atopic dermatitis in pediatric patients 2 to <18 years old: a randomized clinical trial of extended treatment to 3.6 years.Wollenberg A, Ikeda M, Chu CY, Eichenfield LF, Seyger MMB, Prakash A et al. The Journal of dermatological treatment (2024)
    71. [71]
      Comparative efficacy of systemic treatments for atopic dermatitis in adults.Sesi J, Feldman SR Expert review of clinical immunology (2024)
    72. [72]
      Executive summary: Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies.Davis DMR, Drucker AM, Alikhan A, Bercovitch L, Cohen DE, Darr JM et al. Journal of the American Academy of Dermatology (2024)
    73. [73]
      Analysis of Reddit Reveals JAK Inhibitor Questions Among Atopic Dermatitis Patients.Ahuja K, DeSena G, Lio P Journal of drugs in dermatology : JDD (2024)
    74. [74]
      A pathway linking atopic dermatitis to skin microbes.Zhu J Cell host & microbe (2024)
    75. [75]
      Dupilumab: Two sides of a side-effect.Hoeger PH Pediatric dermatology (2024)
    76. [76]
      Atopic dermatitis: new insights into a common condition.Greener M British journal of community nursing (2024)
    77. [77]
      American Academy of Dermatology Guidelines for Managing Atopic Dermatitis.Robinson L, Strowd LC Advances in experimental medicine and biology (2024)
    78. [78]
      From flare to care: Dermatologists' impact on pediatric atopic dermatitis hospital admissions.Wieser JK, Larson BI, Shah SD Pediatric dermatology (2024)
    79. [79]
      Healthcare of patients with atopic dermatitis by general practitioners - a nationwide survey in Germany.Langenbruch A, Andrees V, Scherer M, Augustin M Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG (2024)
    80. [80]
      Teledermatology Versus In-Person Visits for the Follow-Up of Atopic Dermatitis Patients.Odeshi O, Turk T, Fiorillo L, Lowe S, Dytoc M Journal of cutaneous medicine and surgery (2024)
    81. [81]
      Treat-to-target in dermatology: A scoping review and International Eczema Council survey on the approach in atopic dermatitis.Renert-Yuval Y, Del Duca E, Arents B, Bissonnette R, Drucker AM, Flohr C et al. Journal of the European Academy of Dermatology and Venereology : JEADV (2024)
    82. [82]
      Upadacitinib treatment in a real-world difficult-to-treat atopic dermatitis patient cohort.Schlösser AR, Boeijink N, Olydam J, Nijsten TEC, Hijnen D Journal of the European Academy of Dermatology and Venereology : JEADV (2024)
    83. [83]
    84. [84]
    85. [85]
      Effect of weekly vitamin D supplementation on the severity of atopic dermatitis and type 2 immunity biomarkers in children: A randomized controlled trial.Borzutzky A, Iturriaga C, Pérez-Mateluna G, Cristi F, Cifuentes L, Silva-Valenzuela S et al. Journal of the European Academy of Dermatology and Venereology : JEADV (2024)
    86. [86]
    87. [87]
      Systemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials.Chu AWL, Wong MM, Rayner DG, Guyatt GH, Díaz Martinez JP, Ceccacci R et al. The Journal of allergy and clinical immunology (2023)
    88. [88]
      Topical treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials.Chu DK, Chu AWL, Rayner DG, Guyatt GH, Yepes-Nuñez JJ, Gomez-Escobar L et al. The Journal of allergy and clinical immunology (2023)
    89. [89]
      Allergen immunotherapy for atopic dermatitis: Systematic review and meta-analysis of benefits and harms.Yepes-Nuñez JJ, Guyatt GH, Gómez-Escobar LG, Pérez-Herrera LC, Chu AWL, Ceccaci R et al. The Journal of allergy and clinical immunology (2023)
    90. [90]
      Cancer risk with topical calcineurin inhibitors, pimecrolimus and tacrolimus, for atopic dermatitis: a systematic review and meta-analysis.Devasenapathy N, Chu A, Wong M, Srivastava A, Ceccacci R, Lin C et al. The Lancet. Child & adolescent health (2023)
    91. [91]
      Executive summary: American Academy of Dermatology guidelines of care for the management of atopic dermatitis in adults with topical therapies.Sidbury R, Alikhan A, Bercovitch L, Cohen DE, Darr JM, Drucker AM et al. Journal of the American Academy of Dermatology (2023)
    92. [92]
      Meta-analysis on preventive and therapeutic effects of probiotic supplementation in infant atopic dermatitis.Husein-ElAhmed H, Steinhoff M Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG (2023)
    93. [93]
      Global epidemiology of atopic dermatitis: a comprehensive systematic analysis and modelling study.Tian J, Zhang D, Yang Y, Huang Y, Wang L, Yao X et al. The British journal of dermatology (2023)
    94. [94]
      Guidelines of care for the management of atopic dermatitis in adults with topical therapies.Sidbury R, Alikhan A, Bercovitch L, Cohen DE, Darr JM, Drucker AM et al. Journal of the American Academy of Dermatology (2023)
    95. [95]
      Guidelines for the Management of Atopic Dermatitis in Children: A Systematic Review.Wang Q, Liu L, Gao S, Su S International archives of allergy and immunology (2023)
    96. [96]
      European and multi-ancestry genome-wide association meta-analysis of atopic dermatitis highlights importance of systemic immune regulation.Budu-Aggrey A, Kilanowski A, Sobczyk MK, Shringarpure SS, Mitchell R, Reis K et al. Nature communications (2023)
    97. [97]
      Attenuating the atopic march: Meta-analysis of the dupilumab atopic dermatitis database for incident allergic events.Geba GP, Li D, Xu M, Mohammadi K, Attre R, Ardeleanu M et al. The Journal of allergy and clinical immunology (2023)
    98. [98]
      Safety of topical medications in the management of paediatric atopic dermatitis: An updated systematic review.Zhao S, Hwang A, Miller C, Lio P British journal of clinical pharmacology (2023)
    99. [99]
      New molecules for atopic dermatitis treatment beyond biological therapy.Freitas E, Torres T Current opinion in allergy and clinical immunology (2023)
    100. [100]
      English version of Japanese guidance for biologics in treating atopic dermatitis.Saeki H, Akiyama M, Abe M, Igarashi A, Imafuku S, Ohya Y et al. The Journal of dermatology (2023)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG